Istituto di Biostrutture e Bioimmagini-CNR, Napoli, Italy
Fondazione SDN-IRCCS, Naples, Italy
Diagnostic Imaging Department, University Federico II, Naples, Italy
Hematology Department, University Federico II, Naples, Italy
References: Malpas, J. S., Caroll, J. J., (1995) Myeloma: Biology and Management, Myeloma: clinical presentation and diagnosis, pp. 169-190. , eds, New York, NY: Oxford University Press
Angtuaco, E. J., Fassas, A. B., Walker, R., Sethi, R., Barlogie, B., Multiple myeloma: Clinical review and diagnostic imaging (2004) Radiology, 231, pp. 11-23
Durie, B. G., Salmon, S. E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Durie, B. G., Waxman, A. D., D'Agnolo, A., Williams, C. M., Whole-body 18F-FDG PET identifies high-risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Smith, A., Wisloff, F., Samson, D., Myeloma Forum UK
Nordic Myeloma Study Group. British Committee for Standards in Haematology: Guidelines on the diagnosis and management of multiple myeloma 2005 (2006) Br J Haematol, 132, pp. 410-451
Durie, B. G., The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system (2006) Eur J Cancer, 42, pp. 1539-1543
D'Sa, S., Abildgaard, N., Tighe, J., Shaw, P., Hall-Craggs, M., Guidelines for the use of imaging in the management of myeloma (2007) Br J Haematol, 137, pp. 49-63
Zamagni, E., Nanni, C., Patriarca, F., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma (2007) Haematologica, 92, pp. 50-55
Mulligan, M. E., Badros, A. Z., PET/CT and MR imaging in myeloma (2007) Skeletal Radiol, 36, pp. 5-16
Beyer 3rd, R. J., Mulligan, M. E., Smith, S. E., Line, B. R., Badros, A. Z., Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma (2006) Skeletal Radiol, 35, pp. 632-640
Tirovola, E. B., Biassoni, L., Britton, K. E., Kaleva, N., Kouykin, V., Malpas, J. S., The use of 99mTc-MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
el-Shirbiny, A. M., Yeung, H., Imbriaco, M., Michaeli, J., Macapinlac, H., Larson, S. M., Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma (1997) J Nucl Med, 38, pp. 1208-1210
Pace L, Catalano L, Pinto A, et al. M. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med. 1998
25: 714-720Catalano, L., Pace, L., Califano, C., Detection of focal myeloma lesions by technetium-99m-sestamibi scintigraphy (1999) Haematologica, 84, pp. 119-124
Fonti, R., Del Vecchio, S., Zannetti, A., Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma (2001) Eur J Nucl Med, 28, pp. 214-220
Mileshkin, L., Blum, R., Seymour, J. F., Patrikeos, A., Hicks, R. J., Prince, H. M., A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma (2004) Eur J Haematol, 72, pp. 32-37
Pace, L., Catalano, L., Del Vecchio, S., Washout of (99mTc) sestamibi in predicting response to chemotherapy in patients with multiple myeloma (2005) Q J Nucl Med Mol Imaging, 49, pp. 281-285
Hung, G. U., Tsai, C. C., Tsai, S. C., Lin, W. Y., Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma (2005) Anticancer Res, 25, pp. 4737-4741
Martin, M. G., Romero Colas, M. S., Dourdil Sahun, M. V., Olave, P., Alba, P. R., Banzo, J. B., Baseline Tc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance (2005) Haematologica, 90, pp. 1141-1143
Nandurkar, D., Kalff, V., Turlakow, A., Spencer, A., Bailey, M. J., Kelly, M. J., Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake (2006) Eur J Haematol, 76, pp. 141-146
Mele, A., Offidani, M., Visani, G., Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: A multicentre study on 397 scans (2007) Br J Haematol, 136, pp. 729-735
Erten, N., Saka, B., Berberoglu, K., Technetium-99m 2-methoxy- isobutylisonitrile uptake scintigraphy in detection of the bone marrow infiltration in multiple myeloma: Correlation with MRI and other prognostic factors (2007) Ann Hematol, 86, pp. 805-813
Schmidt, G. P., Schoenberg, S. O., Reiser, M. F., Baur-Melnyk, A., Whole-body MR imaging of bone marrow (2005) Eur J Radiol, 55, pp. 33-40
Lucignani, G., Bone and marrow imaging: Do we know what we see and do we see what we want to know? (2007) Eur J Nucl Med Mol Imaging, 34, pp. 1123-1126
Durie, B. G., Kyle, R. A., Belch, A., Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation (2003) Hematol J, 4, pp. 379-398
Bredella, M. A., Steinbach, L., Caputo, G., Segall, G., Hawkins, R., Value of FDG PET in the assessment of patients with multiple myeloma (2005) AJR, 184, pp. 1199-1204
Jadvar, H., Conti, P. S., Diagnostic utility of FDG PET in multiple myeloma (2002) Skeletal Radiol, 31, pp. 690-694
Nanni, C., Zamagni, E., Farsad, M., Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results (2006) Eur J Nucl Med Mol Imaging, 33, pp. 525-531
Schirrmeister, H., Buck, A. K., Bergmann, L., Reske, S. N., Bommer, M., Positron emission tomography (PET) for staging of solitary plasmacytoma (2003) Cancer Biother Radiopharm, 18, pp. 841-845
Moulopoulos, L. A., Gika, D., Anagnostopoulos, A., Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma (2005) Ann Oncol, 16, pp. 1824-1828
Baur-Melnyk, A., Buhmann, S., Durr, H. R., Reiser, M., Role of MRI for the diagnosis and prognosis of multiple myeloma (2005) Eur J Radiol, 55, pp. 56-63
Lecouvet, F. E., Malghem, J., Michaux, L., Skeletal survey in advanced multiple myeloma: Radiographic versus MR imaging survey (1999) Br J Haematol, 106, pp. 35-39
Johnston, C., Brennan, S., Ford, S., Eustace, S., Whole body MR imaging: Applications in oncology (2006) Eur J Surg Oncol, 32, pp. 239-246
Malpas, J.S., Caroll, J.J., (1995) Myeloma: Biology and Management, Myeloma: clinical presentation and diagnosis, pp. 169-190. , eds, New York, NY: Oxford University Press
Angtuaco, E.J., Fassas, A.B., Walker, R., Sethi, R., Barlogie, B., Multiple myeloma: Clinical review and diagnostic imaging (2004) Radiology, 231, pp. 11-23
Durie, B.G., Salmon, S.E., A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Durie, B.G., Waxman, A.D., D'Agnolo, A., Williams, C.M., Whole-body 18F-FDG PET identifies high-risk myeloma (2002) J Nucl Med, 43, pp. 1457-1463
Durie, B.G., The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system (2006) Eur J Cancer, 42, pp. 1539-1543
Mulligan, M.E., Badros, A.Z., PET/CT and MR imaging in myeloma (2007) Skeletal Radiol, 36, pp. 5-16
Beyer 3rd, R.J., Mulligan, M.E., Smith, S.E., Line, B.R., Badros, A.Z., Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma (2006) Skeletal Radiol, 35, pp. 632-640
Tirovola, E.B., Biassoni, L., Britton, K.E., Kaleva, N., Kouykin, V., Malpas, J.S., The use of 99mTc-MIBI scanning in multiple myeloma (1996) Br J Cancer, 74, pp. 1815-1820
el-Shirbiny, A.M., Yeung, H., Imbriaco, M., Michaeli, J., Macapinlac, H., Larson, S.M., Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma (1997) J Nucl Med, 38, pp. 1208-1210
25:714-720Catalano, L., Pace, L., Califano, C., Detection of focal myeloma lesions by technetium-99m-sestamibi scintigraphy (1999) Haematologica, 84, pp. 119-124
Hung, G.U., Tsai, C.C., Tsai, S.C., Lin, W.Y., Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma (2005) Anticancer Res, 25, pp. 4737-4741
Martin, M.G., Romero Colas, M.S., Dourdil Sahun, M.V., Olave, P., Alba, P.R., Banzo, J.B., Baseline Tc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance (2005) Haematologica, 90, pp. 1141-1143
Schmidt, G.P., Schoenberg, S.O., Reiser, M.F., Baur-Melnyk, A., Whole-body MR imaging of bone marrow (2005) Eur J Radiol, 55, pp. 33-40
Durie, B.G., Kyle, R.A., Belch, A., Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation (2003) Hematol J, 4, pp. 379-398
Bredella, M.A., Steinbach, L., Caputo, G., Segall, G., Hawkins, R., Value of FDG PET in the assessment of patients with multiple myeloma (2005) AJR, 184, pp. 1199-1204
Moulopoulos, L.A., Gika, D., Anagnostopoulos, A., Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma (2005) Ann Oncol, 16, pp. 1824-1828
Lecouvet, F.E., Malghem, J., Michaux, L., Skeletal survey in advanced multiple myeloma: Radiographic versus MR imaging survey (1999) Br J Haematol, 106, pp. 35-39
F-18-FDG PET/CT, Tc-99m-MIBI, and MRI in evaluation of patients with multiple myeloma